A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed metastatic adenocarcinoma of the stomach or GEJ
Measurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Life expectancy greater than equal to (\>/=) 3 months
You may not be if
Previous cytotoxic chemotherapy for advanced (metastatic) disease
Evidence of disease progression documented within 6 months after completion of prior neoadjuvant or adjuvant cytotoxic chemotherapy, or both, or radiotherapy for GEJ adenocarcinoma
Previous treatment with any HER2-directed therapy, at any time, for any duration
Previous exposure to any investigational treatment within 30 days before the first dose of study treatment
Radiotherapy within 30 days before the first dose of study treatment (within 2 weeks if given as palliation to bone metastases, if recovered from all toxicities)
History or evidence of brain metastases
Clinically significant active gastrointestinal (GI) bleeding (Grade \>/=2 according to National Cancer Institute \[NIC\]-Common Terminology Criteria for Adverse Events Version 4.0 \[CTCAEv.4.0\])
Residual toxicity resulting from previous therapy (for example, hematologic, cardiovascular, or neurologic toxicity that is Grade \>/=2). Alopecia is permitted
Other malignancy (in addition to gastric cancer \[GC\]) within 5 years before enrollment, except for carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin that has been previously treated with curative intent
Inadequate hematologic, renal or liver function
Pregnant or lactating women
History of congestive heart failure of any New York Heart Association (NYHA) criteria
Angina pectoris requiring treatment
Myocardial infarction within the past 6 months before the first dose of study drug
Clinically significant valvular heart disease or uncontrollable high-risk cardiac arrhythmia
History or evidence of poorly controlled hypertension
Baseline left ventricular ejection fraction (LVEF) value less than (\<) 55 percent (%)
Any significant uncontrolled intercurrent systemic illness
Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection